Literature DB >> 15650264

Targeting multiple myeloma cells and their bone marrow microenvironment.

Guido Pagnucco1, Giovanni Cardinale, Francesco Gervasi.   

Abstract

Although multiple myeloma (MM) is sensitive to chemotherapy and radiation therapy, long-term disease-free survival is rare, and MM remains incurable despite conventional and high-dose therapies. Direct (cell-cell contact) and soluble (via cytokines) forms of interactions between MM cells and bone marrow stroma regulate growth, survival, and homing of MM cells. These interactions also play a critical role in angiogenesis and in myeloma bone disease. In recent years, several studies have established the biologic significance of cytokines in MM pathogenesis and delineated signaling cascades mediating their effects, providing the framework for related novel therapies targeting not only the MM cell, but also the bone marrow microenvironment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15650264     DOI: 10.1196/annals.1322.047

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  22 in total

1.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

2.  Dysfunctional T regulatory cells in multiple myeloma.

Authors:  Rao H Prabhala; Paola Neri; Jooeun E Bae; Pierfrancesco Tassone; Masood A Shammas; Charles K Allam; John F Daley; Dharminder Chauhan; Elizabeth Blanchard; Hemant S Thatte; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Tumorigenic potential and disease manifestations of malignant B-cell variants differing in their fibronectin adhesiveness.

Authors:  Liat Nadav; Vyacheslav Kalchenko; Meir Max Barak; Elizabeth Naparstek; Benjamin Geiger; Ben-Zion Katz
Journal:  Exp Hematol       Date:  2008-08-09       Impact factor: 3.084

4.  Targeting integrin-linked kinase increases apoptosis and decreases invasion of myeloma cell lines and inhibits IL-6 and VEGF secretion from BMSCs.

Authors:  Xiaofang Wang; Zhiqing Zhang; Cheng Yao
Journal:  Med Oncol       Date:  2010-07-13       Impact factor: 3.064

5.  Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.

Authors:  Abdel Kareem Azab; Jinsong Hu; Phong Quang; Feda Azab; Costas Pitsillides; Rana Awwad; Brian Thompson; Patricia Maiso; Jessica D Sun; Charles P Hart; Aldo M Roccaro; Antonio Sacco; Hai T Ngo; Charles P Lin; Andrew L Kung; Ruben D Carrasco; Karin Vanderkerken; Irene M Ghobrial
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

Review 6.  What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.

Authors:  Scott Ely; Noa Biran; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

7.  RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.

Authors:  Abdel Kareem Azab; Feda Azab; Simona Blotta; Costas M Pitsillides; Brian Thompson; Judith M Runnels; Aldo M Roccaro; Hai T Ngo; Molly R Melhem; Antonio Sacco; Xiaoying Jia; Kenneth C Anderson; Charles P Lin; Barrett J Rollins; Irene M Ghobrial
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

8.  Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells.

Authors:  Juwon Park; Vasudevan Ayyappan; Eun-Kyung Bae; Chansu Lee; Byung-Su Kim; Byoung Kook Kim; Young-Yiul Lee; Kwang-Sung Ahn; Sung-Soo Yoon
Journal:  Mol Oncol       Date:  2008-10-07       Impact factor: 6.603

9.  CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

Authors:  Abdel Kareem Azab; Judith M Runnels; Costas Pitsillides; Anne-Sophie Moreau; Feda Azab; Xavier Leleu; Xiaoying Jia; Renee Wright; Beatriz Ospina; Alicia L Carlson; Clemens Alt; Nicholas Burwick; Aldo M Roccaro; Hai T Ngo; Mena Farag; Molly R Melhem; Antonio Sacco; Nikhil C Munshi; Teru Hideshima; Barrett J Rollins; Kenneth C Anderson; Andrew L Kung; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2009-01-12       Impact factor: 22.113

10.  Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP.

Authors:  Li Hua Wang; Xiao Yi Yang; Xiaohu Zhang; William L Farrar
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.